Medical Journals

Anaplasma Marginale Field Challenge: Protection by an Inactivated Immunogen That Shares Partial Sequence of Msp1alpha Variable Region with the Challenge Strain.

Authors:
  • Vega Laura E Orozco
  • Rodríguez Sergio D
  • Alarcón Germinal J Cantó
  • Flores Rafael López
  • Ocampo Rafael Jiménez
  • Ortiz Miguel Angel García
  • de la Torre Jesús Francisco Preciado
  • Ramírez Edmundo E Rojas

From: Campo Experimental Pichucalco, INIFAP, Km 8, Carr. Pichucalco-Teapa, Chiapas, Mexico.

Vaccine

  • Publish Date: Jan 2007
  • ISSN: 0264-410X
  • Volume: 25
  • Issue: 3
  • Pages: 519-25
  • Medium: Print
  • Language: English
  • Citation (JAMA): Vega Laura E Orozco, Rodríguez Sergio D, Alarcón Germinal J Cantó, et al. Anaplasma Marginale Field Challenge: Protection by an Inactivated Immunogen That Shares Partial Sequence of Msp1alpha Variable Region with the Challenge Strain.. Vaccine Jan 2007;25:519-25

Abstract

Twenty four Hereford heifers free of anaplasmosis were allotted into three groups of eight animals each and inoculated three times with adjuvant in Puck saline as control or 50 microg and 100 microg of total protein of Anaplasma marginale initial bodies from three Mexican strains which share the same variable region of msp1alpha and msp4. Inoculation with the adjuvant or the immunogen at either of the two protein doses did not induce any undesirable changes attributable to inoculation in vaccinates or controls. On day 78 post vaccination animals were released in a ranch where bovine Anaplasmosis is endemic. The A. marginale strain prevalent in this ranch shares some of the msp1alpha tandem repeats with and the strains used in the vaccine. After release, all animals became infested with Boophilus microplus ticks and flies. During the challenge period, between days 279 and 300, loss of PCV due to clinical anaplasmosis in control animals was statistically higher from vaccinated animals. Likewise, controls mean peak rickettsemia was also significantly higher (p< or =0.01) than vaccinates’ rickettsemias. The antibody responses of all vaccinates after the third vaccination reached OD values above 2.0 on day 49 and were different from controls (p<0.01). IgG(2) responses from both groups of vaccinates were different from controls (p<0.01). Vaccinates which required treatment, also showed the lowest IgG(2) and substantial IgG(1) responses. After contact with the rickettsia, controls developed clinical disease and 7 out of 8 required treatment, while vaccinates in general showed no substantial changes in hematocrit or rickettsemia and only one animal in each group required treatment. Our present results show that vaccination with either 50 microg or 100 microg of protein from purified IB derived from three strains induced protection to resist the challenge with the a field strain that shares some of the tandem repeats of MSP1a.

Mesh Headings (Keywords): Anaplasma marginale, Anaplasmosis, Animals, Antibodies, Bacterial, Bacterial Outer Membrane Proteins, Bacterial Vaccines, Cattle, Enzyme-Linked Immunosorbent Assay, Female, Immunoglobulin G, Ticks, Vaccination


Check for Full Text / PubMed Unique Identifier (PMID): 17049686


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.